TABLE 2.
The distribution of HLA-B* subgroup frequencies in HIV infected patients and controls
| Genotype | HIV (2n=832) | Control (2n=832) | Statistical analysis | Genotype | HIV (2n=832) | Control (2n=832) | Statistical analysis | ||
|---|---|---|---|---|---|---|---|---|---|
| HLA-B* | n–AF (%) | n–AF (%) | OR-(95% CI) | p | HLA-B* | n–AF (%) | n–AF (%) | OR-(95% CI) | p |
| 07:01 | 2 (0.24) | 6 (0.72) | 0.33 (0.07–1.65) | 0.179 | 39:01 | 10 (1.20) | 4 (0.48) | 2.52 (0.79–8.06) | 0.180 |
| 07:02 | 14 (1.68) | 32 (3.85) | 0.43 (0.23–0.81) | 0.011 | 39:04 | 1 (0.12) | 0 (0.00) | – | – |
| 07:05 | 2 (0.24) | 7 (0.84) | 0.28 (0.06–1.37) | 0.179 | 39:06 | 2 (0.24) | 0 (0.00) | – | – |
| 07:07 | 0 (0.00) | 2 (0.24) | – | – | 40:01 | 20 (2.40) | 23 (2.76) | 0.87 (0.47–1.59) | 0.757 |
| 07:09 | 0 (0.00) | 1 (0.12) | – | – | 40:02 | 2 (0.24) | 4 (0.48) | 0.50 (0.09–2.73) | 0.452 |
| 08:01 | 33 (3.97) | 19 (2.28) | 1.77 (1.00–3.13) | 0.067 | 40:06 | 1 (0.12) | 5 (0.60) | 0.20 (0.02–1.71) | 0.218 |
| 08:26 | 1 (0.12) | 0 (0.00) | – | – | 41:01 | 14 (1.68) | 9 (1.08) | 1.57 (0.67–3.64) | 0.401 |
| 12:01 | 0 (0.00) | 3 (0.36) | – | – | 41:02 | 0 (0.00) | 7 (0.84) | – | – |
| 13:01 | 6 (0.72) | 4 (0.48) | 1.50 (0.42–5.35) | 0.751 | 42:01 | 1 (0.12) | 0 (0.00) | – | – |
| 13:02 | 15 (1.80) | 28 (3.37) | 0.53 (0.28–0.99) | 0.640 | 44:01 | 7 (0.84) | 19 (2.28) | 0.36 (0.15–0.87) | 0.030 |
| 14:01 | 8 (0.96) | 41 (4.93) | 0.19 (0.09–0.40) | <0.0001 | 44:02 | 52 (6.25) | 44 (5.29) | 1.19 (0.79–1.81) | 0.400 |
| 14:02 | 4 (0.48) | 6 (0.72) | 0.67 (0.19–2.37) | 0.751 | 44:03 | 5 (0.60) | 4 (0.48) | 1.25 (0.33–4.68) | 1.000 |
| 15:01 | 43 (5.17) | 25 (3.00) | 1.76 (1.06–2.91) | 0.026 | 45:01 | 4 (0.48) | 0 (0.00) | – | – |
| 15:08 | 1 (0.12) | 2 (0.24) | 0.50 (0.05–5.52) | 0.625 | 46:01 | 3 (0.36) | 5 (0.60) | 0.60 (0.14–2.51) | 0.726 |
| 15:09 | 1 (0.12) | 0 (0.00) | – | – | 47:01 | 2 (0.24) | 3 (0.36) | 0.67 (0.11–4.00) | 0.687 |
| 15:17 | 0 (0.00) | 1 (0.12) | – | – | 47:03 | 0 (0.00) | 1 (0.12) | – | – |
| 18:01 | 53 (6.37) | 66 (7.93) | 0.79 (0.54–1.15) | 0.216 | 48:01 | 9 (1.08) | 3 (0.36) | 3.02 (0.82–11.20) | 0.147 |
| 18:08 | 0 (0.00) | 1 (0.12) | – | – | 49:01 | 44 (5.29) | 30 (3.61) | 1.49 (0.93–2.40) | 0.096 |
| 18:09 | 1 (0.12) | 1 (0.12) | 1.00 (0.06–16.02) | 1.000 | 50:01 | 41 (4.93) | 34 (4.09) | 1.22 (0.76–1.94) | 0.408 |
| 19:01 | 3 (0.36) | 2 (0.24) | 1.50 (0.25–9.01) | 0.687 | 51:01 | 116 (13.94) | 68 (8.17) | 1.82 (1.33–2.50) | 0.0002 |
| 27:02 | 6 (0.72) | 10 (1.20) | 0.60 (0.22–1.65) | 0.451 | 51:05 | 1 (0.12) | 0 (0.00) | – | – |
| 27:03 | 2 (0.24) | 7 (0.84) | 0.28 (0.06–1.37) | 0.179 | 51:07 | 5 (0.60) | 4 (0.48) | 1.25 (0.33–4.68) | 1.000 |
| 27:05 | 1 (0.12) | 0 (0.00) | – | – | 51:08 | 6 (0.72) | 0 (0.00) | – | – |
| 27:07 | 0 (0.00) | 1 (0.12) | – | – | 52:01 | 36 (4.33) | 34 (4.09) | 1.06 (0.66–1.71) | 0.807 |
| 35:01 | 84 (10.10) | 27 (3.25) | 3.35 (2.15–5.22) | <0.0001 | 52:05 | 0 (0.00) | 2 (0.24) | – | – |
| 35:02 | 11 (1.32) | 11 (1.32) | 1.00 (0.43–2.32) | 1.000 | 53:01 | 3 (0.36) | 6 (0.72) | 0.50 (0.12–2.00) | 0.507 |
| 35:03 | 30 (3.61) | 28 (3.37) | 1.07 (0.64–1.81) | 0.789 | 54:01 | 0 (0.00) | 5 (0.60) | – | – |
| 35:04 | 0 (0.00) | 3 (0.36) | – | – | 55:01 | 15 (1.80) | 84 (10.10) | 0.16 (0.09–0.29) | <0.0001 |
| 35:05 | 2 (0.24) | 0 (0.00) | – | – | 56:01 | 5 (0.60) | 0 (0.00) | – | – |
| 35:08 | 20 (2.40) | 5 (0.60) | 4.07 (1.52–10.91) | 0.005 | 57:01 | 10 (1.20) | 17 (2.04) | 0.58 (0.27–1.28) | 0.244 |
| 37:01 | 12 (1.44) | 5 (0.60) | 2.42 (0.85–6.90) | 0.144 | 58:01 | 29 (3.49) | 28 (3.37) | 1.04 (0.61–1.76) | 0.893 |
| 37:03 | 1 (0.12) | 0 (0.00) | – | – | 58:02 | 0 (0.00) | 3 (0.36) | – | – |
| 38:01 | 32 (3.85) | 42 (5.05) | 0.75 (0.47–1.20) | 0.234 | |||||
HLA: Human leukocyte antigen; HIV: Human immunodeficiency virus; AF: Allele frequency; OR: Odds ratio; CI: Confidence interval; 2n: Each individual was represented by two codominant allelic data.